OncoMatch/Clinical Trials/NCT05394259
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Is NCT05394259 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Piflufolastat F18 for pancreatic cancer.
Treatment: Piflufolastat F18 — To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Breast Carcinoma
Hepatocellular Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Patients who have had chemotherapy...within 4 weeks prior to PYLARIFY (piflufolastat F18) injection.
Cannot have received: immunotherapy
Patients who have had...immunotherapy...within 4 weeks prior to PYLARIFY (piflufolastat F18) injection.
Cannot have received: radiotherapy
Patients who have had...radiotherapy within 4 weeks prior to PYLARIFY (piflufolastat F18) injection.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify